Pacer Advisors Inc. Has $13.22 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Key Points

• Pacer Advisors Inc. significantly reduced its stake in Supernus Pharmaceuticals by 74.7%, now holding approximately 403,628 shares valued at $13.22 million.
• Multiple institutional investors have recently adjusted their positions in Supernus Pharmaceuticals, including Raiffeisen Bank, which acquired a new stake valued at around $25,000.
• Wall Street analysts have downgraded Supernus Pharmaceuticals from a "buy" to a "hold" rating, indicating a cautious outlook on the company’s stock performance.

Pacer Advisors Inc. lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 74.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 403,628 shares of the specialty pharmaceutical company's stock after selling 1,193,828 shares during the quarter. Pacer Advisors Inc. owned 0.72% of Supernus Pharmaceuticals worth $13,219,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Raiffeisen Bank International AG bought a new position in Supernus Pharmaceuticals in the 4th quarter valued at $25,000. Financial Management Professionals Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $30,000. Versant Capital Management Inc lifted its stake in shares of Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 1,109 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at $42,000. Finally, Headlands Technologies LLC increased its holdings in Supernus Pharmaceuticals by 203.0% in the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,015 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Cantor Fitzgerald upgraded Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $42.00 price objective for the company in a report on Wednesday. Wall Street Zen cut Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday, July 20th.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN traded up $0.85 during trading hours on Wednesday, hitting $34.30. 122,216 shares of the company traded hands, compared to its average volume of 577,934. The business's 50-day moving average is $32.49 and its 200-day moving average is $33.43. Supernus Pharmaceuticals, Inc. has a twelve month low of $27.05 and a twelve month high of $40.28. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of 30.91 and a beta of 0.70.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.